No Placebo-Only Group

All Individual Drugs Already Approved

Approved for 10 Other Conditions

Pivotal Trial

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer

This study is evaluating whether ovarian function suppression with either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

My cancer has spread to distant parts of my body.

I have had cancer before, but it fits the exceptions.

My breast cancer was confirmed by a biopsy and is hormone receptor positive.

I became postmenopausal after surgery or chemotherapy.

I have noticeable cancer remaining in my underarm area.

I have had breast cancer before, either in the same or the other breast.

I have had surgery to remove both ovaries or radiation treatment on my ovaries.

I am not pregnant or breastfeeding and do not plan to become pregnant in the next 5 years.

I plan to use hormonal therapy in addition to the study treatment for the next five years.

I have been on hormone therapy for my breast cancer for over 8 months.

I was on tamoxifen or similar hormone therapy within a year before my breast cancer diagnosis.

I have received hormone therapy for breast cancer before being considered for this trial.

My estrogen levels are in the premenopausal range.

I haven't had chemotherapy and it's been less than 12 weeks since my surgery.

I finished my chemotherapy less than 8 months ago.

My cancer is only in my breast and nearby lymph nodes, with no spread elsewhere.

My breast cancer cannot be removed with surgery.

I have had surgery to remove lymph nodes or a biopsy showing no cancer in them.

I had surgery for breast cancer and no remaining signs of cancer in the area.

Exemestane

Oophorectomy

Tamoxifen

Triptorelin

The purpose of this study is to compare the decision making of hospitalized subjects having a verbal discussion about CPR compared to subjects using a video.

A Prospective Randomized Trial Using Video Images in Advance Care Planning in Seriously Ill Hospitalized Patients

Video Decision Aid for Advance Care Planning

This study is evaluating whether a video is as effective as a verbal discussion in helping people make decisions about CPR.

Video Decision Aid

Randomized Controlled Trial of a Video Decision Aid in the ICU in surrogates of admitted patients.

A Randomized Controlled Trial of a Video Decision Aid in the ICU

Video Decision Aid for Critical Illness

This study is evaluating whether a video decision aid may help family members make decisions about care for their loved ones in the intensive care unit.

This criterion seems incomplete. Please provide more details.

I am unable to make my own health decisions.

I am in the ICU with a severe illness affecting my heart, kidneys, lungs, GI tract, or due to cancer.

I have an English-speaking representative to make decisions for me.

I am not in the ICU and not imminently dying.

You are very sick and not expected to leave the hospital alive.

Principal Investigator

Combination of guanfacine with opioid medication as a standard treatment for chronic pain.

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

Guanfacine for Hyperalgesia

This study is evaluating whether a combination of guanfacine and opioid medication is more effective than opioid medication alone for chronic pain.

I have used Methadone, Suboxone, Fentanyl, or Tramadol in the past 6 months.

My chronic pain from conditions like fibromyalgia or arthritis is more intense than my back or neck pain.

I am taking medication for high blood pressure that causes low blood pressure or slow heart rate.

I have not been hospitalized for major psychiatric disorders in the past 6 months.

I am currently in a program for substance abuse or taking medication for addiction or ADHD.

You have a history of drug or alcohol abuse as diagnosed by a doctor or admitted by you.

I have a serious heart, liver, kidney, brain, or metabolic condition.

I still have moderate to severe pain despite taking painkillers.

I am taking certain medications that affect my brain's messaging system.

I am currently taking medication that affects how my body processes drugs.

Any new pain treatments I start during the study will be checked by the study doctor.

I experience numbness or tingling in certain areas of my body.

I have been on a stable pain medication dose for 3 months.

You are currently involved in a lawsuit related to neck or back pain.

I have had chronic neck or back pain for at least 6 months.

I cannot sign the consent form by myself due to my condition.

You have tested positive for illegal drugs, marijuana, or drugs not prescribed by a doctor.

You have had a serious allergic reaction to the study medication or any of its ingredients.

I have taken guanfacine or similar medications in the past 6 months.

If your blood pressure is too low when you are sitting, a study doctor will check it.

I have been diagnosed with Raynaud's syndrome.

You take more than 1.6mg of vitamin B2 per day during the study.

Your resting heart rate is less than 60 beats per minute.

Guanfacine

Placebo

Drug Has Already Been Approved

The purpose of this study is to identify individuals 18 or older who have diagnostic presentation of adhesive capsulitis and randomize them into two arms, distinguished by use of physical therapy and steroid injections compared with steroid injections followed by watchful waiting. This prospective study will be used to determine whether there is a significant impact on patient outcome and whether the additional financial burden is justified. There are no experimental interventions for this study. The use of physical therapy, oral and parenteral corticosteroids, and watchful waiting are offered following the standard of care for adhesive capsulitis. Our hypothesis is that patients will not have a significant difference in outcome between the two study arms. One group will undergo regular physical therapy with corticosteroid injections (Arm 1) and the other will have steroid injections during the inflammatory phase only and then be regularly observed (Arm 2). We also hypothesize there will be a significant financial burden associated with the PT arm that is not justified with the possibility of increased symptom reports in that arm.

Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

Physical Therapy and Steroids for Frozen Shoulder

This study is evaluating whether steroid injections are more effective than physical therapy alone for adhesive capsulitis.

I have had surgery for my condition before.

I am willing to be assigned to any treatment group by chance.

I have been diagnosed with frozen shoulder.

Associate Professor of Orthopedic Surgery

Depot Methylprednisolone

Physical Therapy

Approved for 5 Other Conditions

The overall objective of this study is to determine whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.

Early Infant HIV Treatment in Botswana

Early Antiretroviral Therapy for Infant HIV/AIDS

This study is evaluating whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.

You were born after 35 weeks of pregnancy.

You weighed at least 2000 grams at birth.

I can start antiretroviral therapy within 7 days after giving birth.

My newborn was tested for HIV within 4 days after birth and the result was positive or is still pending.

Your blood will be collected and tested for safety reasons before you can participate in the study.

My infant is less than 3 days old at the time of enrollment.

You need to be able to visit the clinic for up to 240 weeks after enrolling in the study.

You qualify for the Botswana government program that provides antiretroviral therapy (ART).

Kaletra

Lamivudine

Nevirapine

Zidovudine

The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Combination Therapy vs Standard Treatment for Kidney Cancer

This study is evaluating whether a combination of lenvatinib and everolimus is more effective than sunitinib.

I have had pneumonitis treated with steroids or have it now.

I am a male who hasn't had a vasectomy and agree to use a condom and spermicide.

My kidney cancer is in an advanced stage.

Your heart takes too long to recharge between beats.

You have high levels of protein in your urine.

Your cholesterol or triglyceride levels are too high when you haven't eaten for a while.

Your diabetes is not well controlled, as shown by a high fasting glucose level.

You currently have a disease where your immune system attacks your own body.

You have at least one specific type of tumor that can be measured and meets certain criteria.

I have had cancer within the last 2 years.

I have not had radiation therapy in the last 21 days.

I haven't taken any experimental drugs in the last 4 weeks.

I still have side effects from recent major surgery.

I have not had significant coughing up of blood or tumor bleeding in the last 2 weeks.

I have an immune system disorder or am on long-term steroids.

My kidney cancer diagnosis includes a clear-cell type.

I have a condition that affects how my body absorbs medication.

I have a bleeding or clotting disorder, or I'm at high risk for severe bleeding.

I am able to care for myself but may not be able to do active work.

I have an active Hepatitis B or C infection.

My cancer has spread to my brain or spinal cord.

I am a woman able to have children and do not agree to use effective birth control.

I have received an organ or tissue transplant from another person.

I have not taken any drugs for kidney cancer that target blood vessel growth.

I have a history of lung disease involving the tissue and space around the air sacs.

I have not received a live vaccine in the last 30 days.

I have not had major heart problems in the last year.

My blood pressure is under control, with or without medication.

Everolimus

Lenvatinib

Pembrolizumab

Sunitinib

The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Capmatinib Safety for Cancer

This study is evaluating whether a drug may help patients with cancer.

I am currently on capmatinib treatment in a Novartis study and can move to another study.

I have not received any live vaccines in the last 30 days.

I am not on any study treatment now due to ongoing side effects.

I am willing and able to follow the study's schedule and procedures.

I am currently benefiting from the treatment in this study.

I am not using effective birth control while on the study treatment.

Capmatinib

Gefitinib

Nazartinib

Osimertinib

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.

Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Repotrectinib for Solid Tumors

I have had cancer before, but it was either skin cancer treated successfully or another type that was completely removed and didn’t need treatment in the last 2 years.

My cancer is advanced and tests show specific gene changes.

I am at least 18 years old, or 20 if required by local laws.

I can swallow pills without breaking them.

All side effects from my previous cancer treatments, except for hair loss, are mild or gone.

I have brain metastases or leptomeningeal disease but no symptoms.

I do not have moderate or severe numbness, tingling, or pain in my hands or feet.

I have previously received immunotherapy.

I haven't had radiation therapy (except for bone pain relief) in the last 2 weeks.

I have brain metastases or leptomeningeal involvement that causes symptoms.

I have had serious heart problems recently.

I have severe lung scarring or disease affecting both lungs.

I have not had major surgery in the last 4 weeks.

I have a condition that affects how drugs are absorbed in my body.

I am fully active or can carry out light work.

I do not have any active infections, including HIV.

Repotrectinib (TPX-0005)

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally or can transition to a Continued Treatment for Trial Participants Open-Label Extension study.

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Risankizumab for Ulcerative Colitis

This study is evaluating whether a drug called risankizumab can help people with ulcerative colitis.

I am not allergic to risankizumab, its ingredients, or products from Chinese hamster ovary cells.

Risankizumab

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months.

Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer

My blood and kidney functions are within normal ranges.

I am not pregnant, breastfeeding, nor planning to become pregnant soon.

I agree to use effective birth control or remain abstinent during and for 90 days after treatment.

I agree to use birth control and not donate sperm for 90 days after my last dose of treatment.

I have had radiation therapy for lung cancer before it spread.

I haven't had any cancer other than NSCLC in the last 5 years, except for certain treated early-stage cancers.

I have a digestive condition that affects how my body absorbs pills.

My liver is not functioning properly due to high enzyme levels or other serious conditions.

I meet all requirements for chemotherapy according to local guidelines.

My lung cancer was surgically removed with clear margins recently.

My lymph nodes were checked for cancer spread without a mediastinoscopy.

I am eligible for platinum-based chemotherapy as per guidelines.

I am HIV positive or have an AIDS-related illness.

I experience symptoms due to a very slow heartbeat.

I have previously been treated with cancer drugs and ALK inhibitors.

My cancer is ALK-positive based on an approved test.

I do not have stage IIIA N2 cancer that requires post-operative radiotherapy.

I have not taken strong medication that affects liver enzymes within the last 14 days.

MGH Clinical Trials 2022

Trials at this site

Video Decision Aid for Advance Care Planning

Video Decision Aid for Critical Illness

Is this your site?

Is this your site?

Patient Reviews